I learned something recently that scared the pants off me.

It began with an extremely esoteric element of U.S. government rules. Specifically, Title 21 of the Code of Federal Regulations, Section 601, Subsections 40-46.

The rules in this subsection give truly extraordinary power to a few individuals. You didn’t vote for a single one of them. But they’ve been entrusted with this power because of their expertise and experience.

You’d think that something of this magnitude would have been on the news. If I were a network news director, I’d have run the story at the top of the telecast. But get this: no major news outlet reported a word of it.

One of two extraordinary things must’ve happened. Either the watchdogs at news organizations like The New York Times missed the story outright…

… or they were ordered to stand down.

Now, let me just warn you. I don’t do hysterics. I don’t overdramatize. The watchword of my premium newsletter, Game-Changing Stocks, is hyper-rationality. 

I’m going to tell you what happened, though. And let me say right now that it has nothing to do with partisan politics. But I think you’ll still feel like your government sucker-punched you square in the gut.

Basically, the mysterious subsections I’m referring to created situations that allow the FDA to suspend the usual rules regarding the clinical trials of new drugs. 

By design, this is to be done pretty rarely — typically only in certain kinds of big-time emergencies. 

But these special exemptions are allowed during times of national security crises… Acts of God… 

Or to put it another way, when the excrement hits the ventilation system.

One of those situations is the very real possibility of a global pandemic outbreak.

Think I’m being overly dramatic?

When asked about a future outbreak, Dr. Rex Archer, Director of Health in Kansas City, Missouri said, “I don’t think there’s any question that we will face another pandemic.”

As Dr. Nils Daulaire, a former president and CEO of the Global Health Council, explained, “We had three pandemics in the 20th century. It’s been almost 40 years since the last one…. we do know from history and from the laws of probability that a global influenza pandemic will happen.” He says that while it’s impossible to predict exactly when, “it’s likely to be in the next 10 to 20 years.”

Now, again, I want to be perfectly clear that I’m not saying some sort of global pandemic is imminent. But if you paid any attention to the news regarding the Ebola outbreaks in Africa last year (and how quickly it spread), then you know that the next potential outbreak of some kind is always around the corner.

I’ve been telling my Game-Changing Stocks readers about this disturbing threat for over a year now. I even predicted that a threatening outbreak would happen — well before the mainstream media began reporting on the Ebola epidemic last year.

I say all this not to pat myself on the back, but to remind you of a few simple facts:

A global pandemic has happened, can happen and — experts say — inevitably will happen again. 

The fact is, these viruses mutate constantly.

The fact is, the world has gotten smaller.

The fact is, people and goods move faster than ever before.

That’s a perfect storm in the making.

The government knows this, too… Which is why I predict that the U.S. government will begin to quietly stockpile record numbers of vaccines in preparation for the next big pandemic.

Let’s face it. As important as this issue is, my Game-Changing Stocks readers don’t pay me to be the town crier. They pay good money for in-depth research, analysis and stock picks that could revolutionize the world and make triple-digit-plus gains for investors in the process.

The good news is, according to my research, there are a handful of publicly-traded companies quietly working on vaccines and treatments for some of the world’s most deadly viruses and diseases. And I’m predicting the U.S. government will significantly bolster its stockpile to combat the next outbreak — and even take advantage of the loophole I mentioned earlier that allows the FDA and drug companies to circumvent the normal regulatory approval process. 

As grim as it might sound, any time Uncle Sam gets involved in a situation like this, it usually translates into a lot of business. 

There’s a lot more to say about this subject. In fact, I think this issue is so important, I decided to cover it in detail in my new report: The 10 Most Shockingly Profitable Predictions for 2016.

I encourage you to check it out. You’ll learn more about this prediction, including how to get the name and ticker symbol of my favorite up-and-coming drug developer working on treatments for a host of dangerous viruses. 

I release this report every year, and it’s made investors gains of up to 189%, 293% and 310% in the past. But this year’s report could be our most controversial yet. To check it out, click here.